

Lifibrol

Catalog No: #S08807



Package Size: #S08807-1 1 mg #S08807-2 10 mg #S08807-3 25 mg #S08807-4 5 mg

Orders: order@signalwayantibody.com

Support: tech@signalwayantibody.com

Description

Product Name	Lifibrol
Other Names	K-12.148;K12148;K-12148;K 12148;Lifibrol;Lipid;cholesterol synthesis;ε ©εO εE η½ ;U-83860;U83860;U83860
Calculated MW	342.43
Storage	Powder: -20°C for 3 years . In solvent: -80°C for 1 year . Shipping with blue ice.

Application Details

ε ε• εO• :C21H26O4Smile:C(CC(COC1=CC=C(C(O)=O)C=C1)O)C2=CC=C(C(C)(C)C)C=C2DMLε• ·:MFCD00865714η!—ε!;98%ζ!Aθ\$ε!;DMSO:50 mg/mL (146.02 mM)δ½ ε ζ»ζ §:Resident peritoneal macrophages isolated from rats pretreated with Lifibrol (50 mg/kg/7 days; mixed into the feed) showed a decreased capacity to synthesize cholesteryl esters from labeled precursors ([1-14C]oleate and [4-14C]cholesterol). Modification of lipid metabolism in atherosclerotic aortae from swine and Watanabe heritable hyperlipidemic (WHHL) rabbits was also observed when the tissues were incubated in vitro in the presence of exogenous Lifibrol.[5]

Concentrations of lifibrol of up to 50 micrograms/mL in the incubations selectively reduced the formation of cholesteryl esters from [1-14C]acetate by 60-75%, whereas higher concentrations (100 micrograms/mL) resulted in a generalized inhibition of lipid biosynthesis of about 50% and of cholesteryl ester formation by up to 90%. The ability of lifibrol to directly affect these targets (i.e. macrophages and arterial tissue) has implications that extend beyond its confirmed plasma cholesterol-lowering activity.[5]δΩ'ε• ·ι θ—:δ»£θ°!• Aη 'H:Lipid

Note: This product is for in vitro research use only and is not intended for use in humans or animals.